Will China’s Postmarket Study Guidelines Accelerate Approvals?
This article was originally published in PharmAsia News
Executive Summary
China FDA has released draft guidelines on conducting Phase IV studies for innovative chemical drugs and therapeutic biologics, indicating the agency’s increasing confidence and risk-management focus. The move could potentially accelerate new drug approvals in China, including biosimilars.